The commercial coverage policy win is a tangible step toward reimbursement, but the widening loss and lack of guidance keep the risk/reward balanced. Monitor the upcoming Medicare coverage decision and Q3 test volumes for signs of accelerating revenue conversion.
Price Chart
Executive Summary
Lucid Diagnostics reported Q2 2026 revenue of $1.5M, up 27% YoY from $1.2M, and processed 2,770 EsoGuard tests. The company secured its first commercial coverage policy from Concert/Lyric, a positive catalyst for reimbursement. However, the GAAP net loss widened to $14.7M from $7.9M YoY, and operating expenses grew 14% to $14.3M, outpacing revenue growth. The company ended the quarter with $33.4M in cash, down from $34.7M at year-end 2025, with no guidance provided.
Key Financial Metrics
Key Facts
- Q2 2026 revenue of $1.5M, up 27% YoY from $1.2M
- Processed 2,770 EsoGuard tests in Q2 2026
- Secured first commercial coverage policy from Concert/Lyric for EsoGuard
- GAAP net loss attributable to common stockholders was $14.7M, vs $7.9M in Q2 2025
- Operating expenses rose to $14.3M from $12.5M YoY
- Cash and equivalents of $33.4M as of June 30, 2026, vs $34.7M at Dec 31, 2025
- Non-GAAP adjusted loss of $10.9M or $(0.06) per share
Financial Impact
Revenue grew $0.3M YoY to $1.5M, but GAAP net loss widened by $6.8M to $14.7M. Cash burn of ~$1.3M from year-end 2025.
Risk Factors
- Widening GAAP net loss and rising operating expenses outpacing revenue growth
- Cash runway limited to into 2027; may require additional financing
- Dependence on Medicare coverage decision for EsoGuard as key catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-037596 |
| Document: form8-k.htm | 0001493152-26-037596 |
| Document: 0001493152-26-037596-index-headers.html | 0001493152-26-037596 |
| Document: 0001493152-26-037596-index.html | 0001493152-26-037596 |
| Document: 0001493152-26-037596.txt | 0001493152-26-037596 |
| 8-K Data (Synthetic) | 0001493152-26-037596 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.4110 $0.5007 | ▼ −21.82% | ▼ −21.11% | $0.5010 (−21.90%) |
Oct 16, 2026 10d ago | 8-K | $0.3770 $0.3520 | ▲ +6.63% | ▲ +6.97% | $0.5010 (−32.89%) |
Sep 22, 2026 4w ago | 8-K | $0.8930 $0.8390 | ▼ −6.05% | ▼ −5.33% | $0.5010 (−43.90%) |
Aug 13, 2026 10w ago | 8-K | $0.9649 $0.9677 | ▲ +0.29% | ▲ +0.49% | $0.5010 (−48.08%) |
May 14, 2026 23w ago | 8-K | $1.02 $0.9910 | ▲ +2.84% | ▲ +1.62% | $0.5010 (+50.88%) |
Apr 24, 2026 26w ago | 8-K | $1.06 $1.04 | ▼ −1.89% | ▼ −1.40% | $0.5010 (−52.74%) |
Apr 23, 2026 26w ago | 8-K | $1.07 $1.06 | ▼ −0.93% | ▼ −1.10% | $0.5010 (−53.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers